Atlas Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Clinical trial NCT03841773 · TERMINATED

Trial details

NCT number
NCT03841773
Sponsor
Tonix Pharmaceuticals, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
PTSD
Start date
2019-03-07
Primary completion
2020-04-24
Enrollment
192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.